Who is sponsoring NCT01478009?

NCT01478009 is sponsored by Chonbuk National University Hospital.

What condition does NCT01478009 study?

NCT01478009 studies Healthy Subjects.

What drugs are being tested in NCT01478009?

Interventions: Korean red ginseng, Placebo.

What is the status of NCT01478009?

NCT01478009 is currently COMPLETED.

Last reviewed 2012-11-26 · How we verify

A Placebo-Controlled Trial of Korean Red Ginseng Extract to Prevent Acute Respiratory Illness in Healthy Subjects

NCT01478009 Phase 2/Phase 3 COMPLETED Results posted

Upper respiratory tract infections are a major source of morbidity throughout the world. Extracts of Korean red ginseng have been found to have the potential to modulate both natural and acquired immune responses. The investigators sought to examine the efficacy of an extract of Korean red ginseng in preventing colds. Therefore, the efficacy and safety of Korean red ginseng will be investigated in healthy subjects during the influenza season.

Details

Lead sponsor	Chonbuk National University Hospital
Phase	Phase 2/Phase 3
Status	COMPLETED
Enrolment	100
Start date	2010-11
Completion	2011-12

Conditions

Healthy Subjects

Interventions

Korean red ginseng
Placebo

Primary outcomes

Frequency of ILI(Influenza Like Illness) — 12 weeks
Subjects received the open-ended questions about frequency of ILI onset during study period. The frequency of ILI onset was checked weekly via telephone.

Countries

South Korea